Vertex Pharmaceuticals has appointed new medical boss and Executive Vice President of global medicines business, which will be effective in the beginning April, to replace Jeffrey A. Chodakewitz who is retireing from his role, but who will remain as Vertex advisor through the first part of the next year.
Reshma Kewalramani, has been appointed Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs, effective April 1, 2018. Dr. Kewalramani currently serves as Senior Vice President, Clinical Development and Medical Affairs at Vertex and will succeed Chodakewitz.
Jeffrey Leiden, Chairman, President and Chief Executive Officer of Vertex, said hes happy to welcome Reshma at her new position as Chief Medical Officer. “Reshma’s depth of medical knowledge, paired with her experience and proven track record as a clinical leader at Vertex, makes her an ideal successor to Jeff. I look forward to working with Reshma to continue to advance our clinical development pipeline in cystic fibrosis and other serious diseases.”